CompletedPhase 4

Treatment of High Altitude Polycythemia by Acetazolamide

Peru55 participantsStarted 2007-01

Plain-language summary

The prevalence of High Altitude Polycythemia (or Chronic Mountain Sickness) is between 8 and 15% in the high altitude regions of South America. There is no pharmacological treatment available. After a first preliminary study in 2003 demonstrating the beneficial effects of acetazolamide in reducing hematocrit in these patients, after 3 weeks of treatment, we want to confirm this effect and implement a treatment protocol of 3 month-duration.

Who can participate

Age range18 Years – 65 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients with Chronic mountain sickness and Hb \> 21g/dl Exclusion Criteria: * patients smokers * patients with respiratory or cardiovascular or renal disease

What they're measuring

Hemoglobin concentration

Timeframe: monthly

Hematocrit

Timeframe: monthly

Trial details

NCT IDNCT00424970

SponsorAssociation pour la Recherche en Physiologie de l'Environnement

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More High Altitude Polycythemia trials